phrykt

Alnylam Pharmaceuticals (ALNY) revenue: $3.7B

Alnylam Pharmaceuticals reported $3.7B of revenue for the year ended Dec 31, 2025, up 65.2% from $2.2B a year earlier.

From Alnylam Pharmaceuticals's filings with the SEC · Read the filing · ALNY stock page

Alnylam Pharmaceuticals revenue by year

$844M2021$1B2022$1.8B2023$2.2B2024$3.7B2025

#854 of 3,622 US companies by revenue · See the full ranking

Year endedRevenueChange
Dec 31, 2025$3.7B+65%
Dec 31, 2024$2.2B+23%
Dec 31, 2023$1.8B+76%
Dec 31, 2022$1B+23%
Dec 31, 2021$844M–

Revenue of similar companies

Companies in the same industry as Alnylam Pharmaceuticals, by SEC industry code, with the closest revenue. Each name opens the same page for that company.

CompanyRevenue, latest yearYear ended
Elanco Animal Health$4.7BDec 31, 2025
Jazz Pharmaceuticals$4.3BDec 31, 2025
PERRIGO$4.3BDec 31, 2025
Alnylam Pharmaceuticals$3.7BDec 31, 2025
Biomarin Pharmaceutical$3.2BDec 31, 2025
United Therapeutics$3.2BDec 31, 2025
Amneal Pharmaceuticals$3BDec 31, 2025

Questions and answers

What is Alnylam Pharmaceuticals's revenue?

Alnylam Pharmaceuticals reported $3.7B of revenue for the year ended Dec 31, 2025, up 65.2% from $2.2B a year earlier.

Numbers as reported in Alnylam Pharmaceuticals's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology